Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines

Darcy Welch; Elliot Kahen; Brooke Fridley; Andrew S Brohl; Christopher L Cubitt; Damon R Reed

doi:10.1371/journal.pone.0222228

. 2019 Sep 24;14(9):e0222228. doi: 10.1371/journal.pone.0222228

Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines

Darcy Welch ^1,^2,^#, Elliot Kahen ^1,^2,^#, Brooke Fridley ^3,^‡, Andrew S Brohl ^4,^5,^‡, Christopher L Cubitt ^2,^‡, Damon R Reed ^1,^4,^5,^6,^*

Editor: Arun Rishi⁷

PMCID: PMC6759167 PMID: 31550266

Abstract

Ewing Sarcoma (ES) is characterized by recurrent translocations between EWSR1 and members of the ETS family of transcription factors. The transcriptional activity of the fusion oncoprotein is dependent on interaction with the nucleosome remodeling and deactylase (NuRD) co-repressor complex. While inhibitors of both histone deacetylase (HDAC) and lysine-specific demethylase-1 (LSD1) subunits of the NuRD complex demonstrate single agent activity in preclinical models, combination strategies have not been investigated. We selected 7 clinically utilized chemotherapy agents, or active metabolites thereof, for experimentation: doxorubicin, cyclophosphamide, vincristine, etoposide and irinotecan as well as the HDAC inhibitor romidepsin and the reversible LSD1 inhibitor SP2509. All agents were tested at clinically achievable concentrations in 4 ES cell lines. All possible 2 drug combinations were then tested for potential synergy. Order of addition of second-line conventional combination therapy agents was tested with the addition of SP2509. In two drug experiments, synergy was observed with several combinations, including when SP2509 was paired with topoisomerase inhibitors or romidepsin. Addition of SP2509 after treatment with second-line combination therapy agents enhanced treatment effect. Our findings suggest promising combination treatment strategies that utilize epigenetic agents in ES.

Introduction

Ewing sarcoma (ES) is the second most common bone sarcoma affecting children and adolescents. Despite advancements in treatment leading to improved outcomes for localized disease over time, prognoses remain poor for patients with recurrent or metastatic disease [1]. ES is characterized by translocations involving members of the ETS family of transcription factors, most commonly t(11;22)(q24;q12) between the amino terminus of the EWSR1 gene and the carboxy terminus of the FLI1 gene, occurring in 85–90% of cases [2, 3]. Efforts to directly target the translocation were reenergized by publication of the ES genomic landscape by three groups demonstrating this alteration to be the only sufficiently recurring change across tumor samples [4–6].

The fusion oncoprotein EWS-FLI1 is considered a transcriptional activator in ES which is required for its oncogeneic activity [3]. A proposed method of targeting the function of the fusion protein is by inhibiting other proteins that may assemble into functional complexes with EWS-FLI1 [7]. EWS-FLI1 transcriptional repression is mediated through direct binding with the nucleosome remodeling and deactylase (NuRD) complex. The NuRD complex consists of histone deacetylases (HDACs), lysine-specific demethylase-1 (LSD1), and other DNA binding proteins and has been shown to play a role in tumor development as well as the general repression of transcription [3, 8]. Disrupting the NuRD complex through inhibition of LSD1, HDAC1, or HDAC2 may block EWS-FLI1 from affecting the transcription of oncogeneic targets. Recent studies have demonstrated that direct targeting of LSD1 with molecular tools leads to significant attenuation of cancer cell proliferation in multiple models [9–11]. Importantly, in preclinical models of ES, reversible inhibitors of LSD1 also demonstrate some promise in halting tumor cell propagation [12]. This strongly influenced our decision to select SP2509 (previously HCI2509) for our studies in lieu of irreversible LSD1 inhibitors such as GSK2879552 or ORY-1001 which have been shown to interfere with flavin adenine dinucleotide (FAD) binding which LSD1 utilizes in histone lysine methylation [13], thereby failing to reduce cell viability in the models tested [14–16]. Additionally, these catalytic inhibitors of LSD1 have been previously tested in ES and found to be insufficient as a therapeutic strategy [17, 18]. SP2509 does not interfere with FAD binding as it interacts with the H3 pocket region of LSD1 which functions as an allosteric site, suggesting that SP2509 may act as an allosteric inhibitor [14]. SP2509 is also currently in Phase I clinical testing (NCT03600649).

HDAC inhibitors have been shown to possess direct antineoplastic activity as well as to enhance the efficacy of other anticancer agents [19]. There is also evidence that inhibition of HDAC inhibition attenuates LSD1 activity in vivo [20]. Despite lackluster results of HDAC therapy in sarcomas, we felt this class warranted investigation as a comparator to LSD1 inhibition due to both being present in the NuRD complex [21, 22].

Due to the rarity of Ewing sarcoma, clinical trials are difficult and time consuming to conduct, increasing the need for preclinical data to direct clinical trials. By targeting the NuRD complex along with agents known to provide clinical benefit we hoped to gain insight into whether or not particular combinations of agents were synergistic or antagonistic. We previously developed a system to efficiently evaluate combinations of interest across multiple cell line models with the goal of rapid translation into relevant clinical trials [23, 24]. Our methodology has been optimized to incorporate past lessons learned from in vitro experiments that did not translate well in clinical applications due to unachievable lengths of exposure or metabolic restraints [25, 26]. All experimental considerations for combination therapy were developed and conducted with the end thought being the eventual clinical trial. We sought to assess LSD1 inhibition and HDAC inhibition in combination with active chemotherapies currently utilized in ES care.

Materials and methods

Investigational agents

Agents used included current standard of care for ES and those of experimental interest (Table 1). Due to the instability of 4-hydroperoxy cyclophosphamide (4HC) and the reversible LSD1 inhibitor SP2509, fresh drug solutions were prepared in DMSO prior to every experiment. MTIC ((5E)-5-(methylaminohydrazinylidene)imidazole-4-carboxamide, the active metabolite of temozolomide) was prepared in 100% ethanol and then mixed 1:1 with media immediately prior to application. Final ethanol concentration never exceeded 1%. Stock solutions for all other compounds were made in DMSO and stored at -20°C. All agents were obtained directly from Selleck Chemicals (Houston, TX, USA), and Sigma-Aldrich (St. Louis, MO, USA). Structures for all agents are available in public databases.

Table 1. Summary of agents tested, mechanism of action, selected pharmacokinetic data, and experimental values—top concentrations and AUC at top concentrations for each drug in each cell line.

				Cell Line Top Conc (ng/ml); AUC at Top Conc (ng/ml*24hr)
Agent	Mechanism of Action / Reference	Cmax (ng/ml)	AUC (h*ng/ml)	A673	RD-ES	TC32	TC-71
4HC¹	DNA Crosslinking, DNA Damage	6927	27700–33000	2000; 48000	2000; 48000	4000; 96000	4000; 96000
4HC¹	McCune JS, et al.(2009) J Clin Pharm; Kahen EJ, et al.(2016) Can Chem Pharm
Doxorubicin	DNA, topo II	2109	945	160; 3840	600; 14400	80; 1920	160; 3840
Doxorubicin	Greene RF, et al.(1983) Cancer Res; Bartlett NL, et al.(1994) J Clin Oncol
Etoposide	Topoisomerase II, DNA Damage	20000	157000	300; 7200	800; 19200	800; 19200	800; 19200
Etoposide	Kaul S, et al. (1995) Anticancer Drugs
Romidepsin	Class I/II HDAC	377	2414	4; 96	4; 96	4; 96	4; 96
Romidepsin	Fouladi M, et al.(2006) J Clin Oncol
SN-38²	Topoisomerase IB	30	104	1; 24	0.75; 18	0.75; 18	0.75; 18
SN-38²	Ma MK, et al.(2000) Clin Cancer Res
SP2509^†	LSD1 inhibitor	3000	TBD	1000; 72000	1000; 72000	2000; 144000	2500; 180000
SP2509^†	Fiskus W., et al.(2012) J Clin Oncol
MTIC³	Alkylator	13000	46000	250; 6000	NA	250; 6000	NA
MTIC³	Horton TM, et al.(2007) J Clin Oncol
Vincristine	Microtubules, Anti-mitotic	40	90	2; 48	0.6; 14.4	2; 48	3; 72
Vincristine	Guilhaumou R, et al.(2011) Cancer Chemother Pharmacol

Open in a new tab

†Value determined in rats

¹Active metabolite of cyclophosphamide

²Active metabolite of irinotecan

³Active metabolite of temozolomide

Cell culture

We selected four ES cell lines that are well characterized and commonly used in recent studies (Table 2) [3, 12, 27]. A673 was obtained from the ATCC (Manassas, VA). The TC32 (Children’s Oncology Group (COG) Cell Line & Xenograft Repository), TC-71 (National Cancer Institute (NCI) Pediatric Preclinical Testing Program) and RD-ES cells lines were generously shared by Dr. Stephen Lessnick. A673 Cells were maintained in DMEM with 10% fetal bovine serum. TC-71, RD-ES and TC32 cells were maintained in RPMI with 15% fetal bovine serum. While protein binding can impact the activity of anti-cancer agents [28], these 15% concentrations are higher than human albumin concentrations. Media was supplemented with PenStrep prior to extended incubation times. Cells were grown at 37°C and 5% CO₂. All cell lines tested free of mycoplasma using MycoAlert tests (Lonza Rockland, Rockland, ME). Cell line authentication was confirmed using StemElite ID system (Promega, Madison, WI) and comparing results to the ATCC, COG, and NCI short tandem repeats (STR) profiles.

Table 2. Summary of Ewing cell lines.

Cell Line	ATCC Designation	Tissue	Doubling Time (hours)	Diagnosis	Patient Info	EWS-FLI1 translocation t(11;22)(q24;q12)	FLI1-EWS Reciprocal Fusion	TP53	KDM1A mRNA Expression Level^g	STAG2 Status^h^,ⁱ
A673	ATCC® CRL-1598^™	Muscle^a	25^c	Ewing's Sarcoma^a	15 year old female^a	Type 1 Fusion^d	Detectable^d	Non-functional (p.A119 frameshift)^c^,^f	8.49 ± 1.29	Wildtype
RD-ES	ATCC® HTB-166^™	Bone^a	60^k	Ewing's Sarcoma^a	19 year old male^a	Type 2 Fusion^e	Unknown	Mutant (p.R273C)^f	5.66 ± 0.75	No Expression
TC32	N/A	Bone^b	24^c	PNET^b	17 year old female^b	Type 1 Fusion^e	Unknown	Functional (Wildtype)^c	2.32 ± 0.23	I636sf
TC-71	N/A	Ileum^c	21^c	Ewing's Sarcoma^b	22 year old male^b	Type 1 Fusion^d^,^e	Undetectable^d	Non-functional (p.R213 nonsense)^c^,^f	3.14 ± 0.50	Wildtype

Open in a new tab

^aATCC

^bChildren's Oncology Group (COG) Cell Culture and Xenograft Repository

^cMay, W.A., et al. Characterization and Drug Resistance Patterns of Ewing's Sarcoma Family Tumor Cell Lines. PLoS One. 2013; 8(12): e80060.

^dElzi, D.J., et al. The role of FLI-1-EWS, a fusion gene reciprocal to EWS-FLI-1, in Ewing sarcoma. Genes Cancer. 2015 Nov; 6(11–12): 452–461.

^eHuang, H.J., et al. R1507, an Anti-Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antibody, and EWS/FLI-1 siRNA in Ewing's Sarcoma: Convergence at the IGF/IGFR/Akt Axis. PLoS One. 2011; 6(10): e26060.

^fTirode, F., Sirdez, D., et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov. 2014 Nov; 4(11): 1342–1353.

^gPishas, P.I., et al. Therapeutic targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response. Molecular Cancer Therapeutics. 2018 Sep; 17(9): 1902–1916.

^hCrompton, B.D., et al [5]

ⁱBrohl, A.S., et al [4]

^kHyper Cell Line Database

Cell viability assays

The activity of drugs alone and in combination was determined by a high-throughput cell viability assay as described previously [23, 24]. Cells (4.5 x 10³ per well) were transferred to 384-well plates and incubated for 24 hours prior to drug administration, which was empirically confirmed to be a period of log-phase growth for these conditions. At 72 hours, cell viability was assessed using CellTiter-Glo (CT-Glo) (Promega, Madison, WI, USA), which provides luminescence proportional to cellular ATP levels. This reflects the reduction in cellular metabolism (an indication of cell viability) due to the drug treatment. Data were transferred to custom Microsoft Excel templates and the percent viability/fraction affected was calculated by normalization to untreated control conditions. Specifically, FA is calculated as FA = 1 –(CT-glo signal with drug treatment)/(CT-glo signal without drug treatment). Absolute IC50 values were determined using sigmoidal equilibrium model regression and fitted using XLfit version 5.5 (ID Business Solutions, Guildford, Surrey, England). The IC50 values obtained from single-drug viability assays were used to design subsequent drug combination experiments.

Single-agent screening

Single agent dose response was characterized for a panel of 7 therapeutic candidates across 4 ES cell lines (A673, RD-ES, TC32 and TC-71) (Table 2). Human pharmacokinetic data was collected using pediatric and combination studies when available from previously reported Phase I trials. The majority of drugs selected (excluding only romidepsin and SP2509) have half-lifes greater than 8 hours or have a continuous dosing schedule clinically. The half-life of SP2509 is unknown in humans. We chose to uniformly expose the cells for 72 hours to all the drugs. Experiments were performed in triplicate with at least 4 technical replicates per biological replicate.

Two-drug combination screening

A 5x5 checker-board matrix was used to assess all two-drug combinations at five clinically achievable concentrations. Each combination was evaluated at multiple drug ratios to identify synergy. Analysis of additive and synergistic effects was done by measuring cell viability with the CellTiter-Glo assay with results analyzed using the Combination Index (CI) method of Chou-Talalay [29]. CI, a measure of drug synergy, is derived by taking the dose-effect curve for each drug using the median effect principle and then comparing it to the effect achieved with the 2-drug combination. 2-drug combination activity that is merely additive is represented by a CI value of 1.0. As CI decreases below 1.0, drug synergism increases. Antagonistic drug effects are indicated by a CI greater than 1.0. A minimum of two biological replicates per cell line were performed with at least 4 technical replicates per condition in each experiment.

Order of addition assays

A673 and TC32 cells (2.25 x 10³ and 4.5 x 10³ per well, respectively) were transferred to 384-well plates and incubated for 24 hours prior to initial drug administration. Cells were then treated with one, two or three drugs concurrently at the chosen top concentration, one half, and one quarter of the top concentration, and incubated for an additional 24 hours. Experimental plates were then read on Day 2 with RealTime-Glo (RT-Glo) (Promega, Madison, WI, USA) (proprietary technology) before being treated with an additional drug. Plates were then read a second time 72 hours later on Day 5, and final cell viability results were obtained. Experiments were performed in duplicate plus an additional run with higher cell numbers with 12 technical replicates per condition in each experiment.

Statistical methods

The drug response data was modeled using a sigmoidal equilibrium regression curve using the software package XLfit version 5.5. Differences between drug response measurements (i.e., FA values) between drug combinations was completed using linear mixed effects model with a random intercept for cell lines to account for multiple measurements taken off the same cell line with a fixed effect adjustment for concentration level of the drug using R package lme4. For comparisons between the 21 drug combinations a Bonferroni adjustment for multiple testing was used.

Results

NuRD complex directed therapeutics demonstrate considerable in vitro activity at clinically achievable levels

We characterized the single-agent activity of a panel of 7 therapeutic candidates (Table 1) using 4 ES cell lines (A673, RD-ES, TC32 and TC-71) (Table 2). The active metabolite of the alkylating prodrug cyclophosphamide, 4HC; the DNA intercalator and topoisomerase II inhibitor, doxorubicin; the topoisomerase II inhibitor, etoposide; the active metabolite of the topoisomerase I inhibitor irinotecan, SN-38; and the Beta-tubulin inhibitor, vincristine were chosen due to their role in first and second line treatment of ES. The additional 2 agents, the HDAC1 and HDAC2 inhibitor romidepsin and the reversible LSD1 inhibitor SP2509, were selected based on their respective targets in the NuRD complex [3]. To evaluate the potency of these agents, full dose-response curves were obtained for the drug panel in each cell line. As anticipated, cell lines showed sensitivity to agents used clinically in the management of ES. In addition, experimental candidates romidepsin and SP2509 demonstrated potency in the single agent context. The half maximal inhibitory concentrations (IC50s), simulated maximal plasma concentrations (Cmax), and area under the curves (AUC) were within clinically achievable levels for all drugs selected in nearly all contexts (Fig 1, Table 1, Table 2). Some variability between cell lines was observed with A673 and TC-71 demonstrating a trend towards tolerance relative to RD-ES and TC32; however, cell line drug sensitivities were mostly uniform across the cell lines and were uniform for vincristine. A673 demonstrated a relative tolerance to topoisomerase inhibitors while TC-71 was more tolerant to alkylators and epigenetic agents (S1 Table).

Fig 1 — Dose response plots of each drug tested across 4 cell lines plotted as fraction affected (FA) versus concentration (ng/ml). Data was recovered 72 hours after drug treatment. Plotted points represent the mean FA values while error bars represent ±SEM (standard error of the mean) between technical replicates. Arrows beyond the x-axis indicate a Cmax in excess of the values displayed.

The LSD1 inhibitor SP2509 and the HDAC inhibitor romidepsin are synergistic with conventional chemotherapeutic agents in vitro

We hypothesized that agents that interact with components of the NuRD complex would work synergistically with agents already utilized in the treatment of ES. We performed high throughput cell viability assays that assessed each of the 7 agents in combination at 25 different concentration pairs. All drugs were tested below Cmax values and spanned the IC50 for each cell line to allow for synergy (combination index, CI) calculations. We identified multiple drug combinations that demonstrated high fraction affected (FA) values (see methods for further discussion of CI and FA). The FA and CI values of each drug combination and drug ratio in each individual cell line are summarized in S2 Table in order of top performing combinations. The average distribution of effects for each drug combination trends toward high FA and low CI values when paired with SP2509 or romidepsin. (Fig 2A and 2B, respectively). SP2509 generally showed synergy with all drugs apart from vincristine which demonstrated antagonism at most concentrations in this combination. Combinations containing romidepsin, while still trending towards high FA and low CI, were less synergistic than those with SP2509 overall, experiencing antagonistic drug interactions with vincristine as well as etoposide. In order to gain a comprehensive overview of FA across all cell lines and concentrations, statistical analysis was performed using a linear mixed effects model with a random intercept for cell lines and a Bonferroni adjustment for multiple testing (adjusting for 210 tests, a p-value of 0.0002 is considered significant; see methods for further discussion of statistical analysis). Our analysis showed that of the six possible combinations with SP2509, all the combinations produced a more significant FA than SP2509+4HC (Fig 2C). Combinations SP2509+romidepson, SP2509+doxorubicin, and SP2509+vincristine all produced FAs more statistically significant than SP2509+etoposide. And the FA of the SP2509+vincristine was more statistically significant than the combination of SP2509 with 4HC, etoposide, and doxorubicin. When the same analysis was performed with romidepsin combinations, we found romidepsin+doxorubicin, romidepsin+SN-38, and romidepsin+vincristine to have the most statistically significant FAs (Fig 2D). Romidepsin+vincristine had the most statistically significant FAs, more significant than when paired with etoposide, SP2509, and 4HC. Interestingly, nearly all the combinations produced higher FA values than those produced with romidepsin+SP2509.

When viewed comparatively between cell lines, sensitivity differences to combinations containing SP2509 or romidepsin were observed (Fig 2C, 2D, 2E and 2F, S2 Table). A673 was typically more resistant to drug pairs with SP2509 (Fig 2C). Except for SP2509+vincristine, FA values trended lower than the other cell lines, though this is likely due more to A673’s sensitivity to vincristine. This sensitivity is likely to have skewed the statistical analysis for this combination, making the FA appear more significant for this combination than its actual performance across all the cell lines. RD-ES and TC32 were similar in their drug tolerances, mostly demonstrating high median and maximum FA values. TC-71 had the largest distributions of effects across all the combinations tested, though kill rates near 100% (FA near 1.0) were still reached for all combinations with SP2509. The distribution of CI values for SP2509 combinations was similar in RD-ES and TC-71 with median values between 0.5 and 0.8 (Fig 2E). SP2509 synergism in TC32 was more greatly distributed showing antagonism at some concentrations and synergism at others. FA values for combinations containing romidepsin were more mixed (Fig 2D). The most notable differences compared to SP2509 combinations include the relative resistance of RD-ES and the notable potency of romidepsin+vincristine in A673. Synergism was consistently observed in combinations containing romidepsin with TC32 displaying higher values at more concentrations than in other lines (Fig 2F). The resistance of RD-ES to these combinations is associated with highly distributed CI values. The combination of SP2509 with romidepsin itself was rather effective, producing median FA values near and above 0.7 across all cell lines except TC-71, with maximum FA values of 1.0 reached in all 4 ES models (Fig 2A, 2B, 2C, 2D, 2G and 2I). Synergy between the drugs was also consistently seen (average CI = 0.4), with TC32 having a bit of a larger distribution across all concentrations tested compared to the other lines (Fig 2B, 2E, 2F and 2Gi). Notably, even at lower concentrations of both drugs, high FA and low CI values were typically still observed.

Topoisomerase inhibitors showed particularly strong activity and synergy when paired with SP2509. SP2509 and any of doxorubicin, etoposide or SN-38 demonstrated an average FA of at least 0.87, with FA as high as 0.95 observed in two cell lines and average CIs of 0.5 or lower (Fig 2A, 2C, 2E and 2Giii,iv, S2 Table). We were particularly interested in the translational potential of combining SP2509 with etoposide since oral etoposide is often used in the relapsed setting, continuously dosed, and well tolerated in patients. At lower concentrations of etoposide, combined with the top concentration of SP2509, FA was 0.88 (Fig 2Giii) and minimum CI values of 0.4 (Fig 2Giv) were obtained. Synergy was achieved at all except the lowest concentrations of SP2509.

SP2509 enhances efficacy of VIT (vincristine, irinotecan, and temozolomide)

In order to further investigate the translational potential of SP2509, we administered it in combination with the conventional treatment utilized in relapsed ES, VIT: Vincristine, Irinotecan (SN-38, the active metabolite), and temozolomide (MTIC, the active metabolite)[30, 31]. We chose two cell lines, A673 and TC32, which we felt would be representative of our cell lines and had diversity amongst the other genes that may play a role in eventual subtyping of Ewing sarcoma, TP53 and STAG2. TC32 has a functional p53 gene while A673 has a frameshift mutation rendering p53 nonfunctional. Conversely, A673 is wild type for STAG2 whereas TC32 has a frameshift mutation in STAG2 (Table 1) [4, 27, 32]. We assayed for potential differences in potency with this 4-drug combination by testing multiple orders of addition of the agents as well as one half and one quarter concentrations of what we estimated would be an optimal top concentration (Fig 3A and 3B, S1 Fig). Utilizing RT-Glo, we were able to obtain multiple timepoints of the same experimental plate, which allowed us to observe drug kinetics over time. We found that the effects on viability from SN-38 were more delayed than any of the other agents. This was most noticeable in A673 where there was a 50-fold shift in the IC50 between 24-hours and 96-hours (40ng/ml vs 0.77ng/ml, respectively) (Table 3). The practical result of this is that combination FAs were typically higher when SN-38 was added first rather than second (Fig 3A and 3B; S1 Fig). TC32 appears to be more sensitive overall with the exception of vincristine, though this may simply be due to the differences in doubling times. Indeed, because of the speed of A673 proliferation, cell numbers needed to be halved to make it compatible with this protocol due to considerable variability between experiments (S1C Fig). The particular sensitivity of A673 to vincristine in this context is worth further study. Importantly, at concentrations well below Cmax (Table 3, S1A Fig), combinations of VIT+SP2509 were able to reduce cell viability by over 90% at the highest-tested concentrations and by over 80% at half the topmost concentrations. It should be noted that due to the instability of MTIC, the actual concentrations in media are likely below the calculated estimate. In A673, there is no clear preference for any particular order of addition with these 4 agents, though the largest increase between Day 2 and Day 5 was seen when SP2509 was added last. In TC32, there is a tendency towards higher potency when SP2509 is added last, but this is within the bounds of experimental variability. Overall, addition of SP2509 increased the FA but only slightly, most likely due to the already efficacious treatment of VIT alone. However, this increase can be noted at lower concentrations as well as when SP2509 is substituted for one of the other drugs in combination (S1 Fig).

Fig 3 — Results of order of addition experiments for a) A673 and b) TC32, respectively. One to three drugs were given concurrently 24 hours after plating and read on Day 2. The fourth drug was added after the 48 hour read and the same experimental plate was read on Day 5. TOP represents the highest concentration used as indicated in Table 3B; ½ is half the highest concentration, ¼ is a quarter of the highest concentration. Error bars represent standard error of the mean. A673 n = 2, TC32 n = 4. See S1 Fig for all order of addition results.

Table 3. Single agent dose response IC₅₀s at 24-hours and 96-hours after treatment, ± standard error of the mean.

Tx	A673		TC32		Top Concentration	Cmax (ng/ml)
Tx	Day 2	Day 5	Day 2	Day 5	Top Concentration	Cmax (ng/ml)
MTIC	18889 ± 3240	18915 ± 3672	15547 ± 7867	9447 ± 4045	250	276
SN38	40 ± 33	0.77 ± 0	4.0 ± 0.5	2.6 ± 0.2	4	30
SP2509	4222 ± 863	1171 ± 212	2375 ± 221	1238 ± 89	1000	3000
Vincristine	0.73 ± 0.25	0.79 ± 0.03	6.2 ± 1.4	2.0 ± 0.3	1	40

Open in a new tab

Discussion

In this study, our aim was to evaluate the inclusion of romidepsin and SP2509, both NuRD complex-directed therapeutics, with agents currently utilized in the treatment of ES. Our results confirm that ES cell lines are sensitive to multiple chemotherapeutic agents commonly used in ES treatment and the addition of NuRD complex-directed drugs show promising results as potential additions to future chemotherapeutic regimens. A summary of the top performing agents is included in S3 Table. When considering promising agents for ES, the practicalities of the chemotherapeutic regimen should be considered early in order to best inform eventual trial approaches which will incorporate a new agent. Standard initial therapy for ES includes a clinical trial when available and in the United States typically is based on every 2 week therapy with vincristine, doxorubicin and cyclophosphamide alternating with ifosfamide and etoposide [33]. Relapse studies typically incorporate a camptothecin (either topotecan or irinotecan) with an alkylating agent (typically cyclophosphamide or temozolomide respectively) or oral etoposide when a trial is not available [34].

As of this writing, optimal schedule, toxicities, adverse effects and maximal tolerated doses with resultant PK are not yet available for reversible LSD1 inhibitors in humans. Trials are open with SP2577, a similar compound, in the Ewing sarcoma population with continuous dosing schedules, NCT03600649. Importantly, when SP2509 is combined with current second-line conventional chemotherapy regimen vincristine, irinotecan, temozolomide (VIT) in vitro, cell viability is considerably decreased even at concentrations well below Cmax. The concentrations used in these experiments are well below the observed maximal plasma concentrations observed in pharmacokinetic assays and thus it is possible that sufficient efficacy could be achieved at lower than maximally tolerated doses, which may minimize side effects and maximize additional agents being combined in the future. 4HC, etoposide, doxorubicin, and SN-38 all exhibited robust activity alone and in combination with SP2509, which was confirmed when we performed a correlation analysis on the FA of all combinations tested (Fig 4). If indeed SP2509 is acting as an LSD1 inhibitor, LSD1 is required for heterochromatin formation [35, 36]. When inhibited, DNA would be structurally less dense and more open to agents that damage DNA such as topoisomerases, which correlates well with our findings.

Fig 4 — Spearman correlation between FA values from four cell lines treated with the various drug combinations. Blue values indicate strong positive correlation while red values indicate strong negative correlation between drug FA values.

Of note is the antagonism exhibited when SP2509 and vincristine are paired in the A673 cell line. A possible explanation is the unique sensitivity of A673 to vincristine, disallowing synergy. Inhibition of the EWS-FLI1 fusion protein has been shown to decrease EWS-FLI1-mediated generation of microtubule-associated proteins leaving cells more susceptible to microtubule depolymerization by vincristine [37]. Real time quantitative PCR for the EWS/ETS gene product as well as the native FLI1 showed the lowest expression of EWS/ETS in A673, followed by TC32 and then TC-71 (RD-ES was not tested) [38]. However, it has also been shown that levels of the EWS-FLI1 transcript and protein are heterogeneous from one cell to another and can range from low to high expression levels and fluctuate along time, producing different phenotypes of cell proliferation, migration, invasion and metastases [39]. Clearly more investigation is required before a definitive assessment of these mechanisms can be ascertained. Another possibility is that the cell lines have relative resistance to vincristine from prior exposure. Indeed, TC-71 and TC32 were derived post chemo, RD-ES was derived from a primary osseous of the humerus, and it is unknown whether A673 was derived pre- or post-chemotherapy. A673 was derived in 1973 and it is known that lower doses of chemotherapy were administered then, but vincristine most likely would have been used [38]. This does not seem to be generalizable to all microtubule inhibitors as when SP2509 was administered with docetaxel to prostate cells, synergy is noted at sub-IC₅₀ doses [40].

Another possible translational route would be combining an epigenetic agent with oral etoposide. This route has the advantages of long exposures of both agents at effective concentrations along with the fewest side effects of the chemotherapeutic backbone. An additional potential advantage of combination strategies utilizing SP2509 beyond its distinct mechanism of action is the potential feasibility of continuous dosing. We postulated a clinical dosing schedule for one week with oral etoposide paired with SP2509 and romidepsin (Fig 5). In the case of SP2509 and etoposide, multiple opportunities for synergism exist at the concentrations used and times administered. Recent combination data with vincristine and translocation targeting agents such as TK216 are also being reported [37]. The findings here of synergy and activity at low levels are especially interesting due to their clinical applications.

Fig 5 — Dosing schedules for a 7-day treatment of oral etoposide paired with SP2509 and romidepsin. Plasma concentrations and estimated half-life for single-drug administration are derived from sources listed. Values in red indicate plasma concentrations comparable to experimental concentrations used. Values in boxes represent expected FA at given concentrations. Color represents amount of synergy expected. Gray boxes represent untested concentration combinations.

We demonstrated that the HDAC inhibitor romidepsin would also be a promising addition to standard chemotherapy agents utilized in relapsed or refractory Ewing sarcoma. Even though multiple opportunities for synergism do not exist as in the case of etoposide and SP2509, romidepsin has been shown here to be effective even at lower concentrations and could prove synergistic beyond the levels we tested. Epigenetic modification is particularly of interest in a malignancy like ES which is characterized by a translocation altering transcriptional control. HDACs are involved in a broad number of biological pathways, and interruption of their function can result in a plethora of transcriptional and functional consequences [41]. Sankar et. al. demonstrated that transcriptional repression of EWS-FLI1 is mediated through direct binding of the NuRD complex and that NuRD-associated HDAC and LSD1 functions are vital to this repression [3].

Of additional interest is the fact that we also saw synergistic activity when SP2509 was paired with romidepsin. These findings are consistent with other studies that investigated the co-administration of LSD1 and HDAC inhibitors in other cancer models as well as recent developments with a dual LSD-1/HDAC hybrid inhibitor [19, 42–44]. Although the most significant FA values we obtained with romidepsin were with drugs that utilized a different mechanism of action, our findings of synergism with SP2509 suggest that the addition of both agents into the current ES treatment could prove beneficial, but further investigation is required.

The methods presented here demonstrate a comprehensive, reproducible, and high-throughput method for exploring antitumor effects of combinations of therapies at clinically achievable concentrations. In particular we discovered that combinations of SP2509 with currently utilized conventional chemotherapies demonstrate largely synergistic activity against ES cell lines. Several combinations seem to have translational promise. Combining SP2509 with oral etoposide would maximize the potential time that both agents can be maintained at therapeutic levels. Combining with VIT would be of interest as well and consideration for timing of SP2509 should be further considered. Additional explorations of these combinations through available murine models are recommended as well as extended assays to see the effects of long-term drug treatment.

Supporting information

S1 Fig. All order of addition results including two-drug, three-drug, and four-drug combinations as discussed in Fig 3.

a) A673 (2250 cells), b) TC32 (4500 cells), c) A673 (4500 cells).

(TIF)

Click here for additional data file.^{(3.4MB, tif)}

S1 Table

A) Average IC₅₀ ± standard error. B) IC₅₀ ± standard error as a % of Cmax. C) IC₅₀ ± standard error with conditional formatting indicating % Cmax.

(TIFF)

Click here for additional data file.^{(685.4KB, tiff)}

S2 Table. Full table of two-drug combinations.

(DOCX)

Click here for additional data file.^{(377.7KB, docx)}

S3 Table. Top combination treatment regimens based on a combination of FA and CI.

(TIF)

Click here for additional data file.^{(5.4MB, tif)}

Acknowledgments

We thank Dr. Kathleen Pishas for critical review of the manuscript.

Abbreviations

LSD1: lysine-specific demethylase 1
ES: Ewing sarcoma
NuRD: nucleosome remodeling and deacetylase co-repressor complex
HDAC: histone deacetylase
4HC: 4-hydroxycyclophosphamide
FA: fraction affected
FAD: flavin adenine dinucleotide
CI: combination index
IC₅₀: half maximal inhibitory concentrations
Cmax: maximal plasma concentrations
AUC: area under the curve
MTIC: (5E)-5-(methylaminohydrazinylidene)imidazole-4-carboxamide

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

This study was generously supported by the National Pediatric Cancer Foundation (www.nationalpcf.org). This work has been supported in part by the Translational Research Core at the H. Lee Moffitt Cancer Center & Research Institute, a NCI designated Comprehensive Cancer Center (P30-CA076292). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1.Gorlick R, Janeway K, Lessnick S, Randall RL, Marina N, Committee COGBT. Children's Oncology Group's 2013 blueprint for research: bone tumors. Pediatr Blood Cancer. 2013;60(6):1009–15. 10.1002/pbc.24429 [DOI] [PMC free article] [PubMed] [Google Scholar]
2.Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992;359(6391):162–5. 10.1038/359162a0 [DOI] [PubMed] [Google Scholar]
3.Sankar S, Bell R, Stephens B, Zhuo R, Sharma S, Bearss DJ, et al. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. Oncogene. 2013;32(42):5089–100. 10.1038/onc.2012.525 [DOI] [PMC free article] [PubMed] [Google Scholar]
4.Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, et al. The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genet. 2014;10(7):e1004475 10.1371/journal.pgen.1004475 [DOI] [PMC free article] [PubMed] [Google Scholar]
5.Crompton BD, Stewart C, Taylor-Weiner A, Alexe G, Kurek KC, Calicchio ML, et al. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov. 2014;4(11):1326–41. 10.1158/2159-8290.CD-13-1037 . [DOI] [PubMed] [Google Scholar]
6.Tirode F, Surdez D, Ma X, Parker M, Le Deley MC, Bahrami A, et al. Genomic Landscape of Ewing Sarcoma Defines an Aggressive Subtype with Co-Association of STAG2 and TP53 Mutations. Cancer Discovery. 2014;4(11):1342–53. 10.1158/2159-8290.CD-14-0622 [DOI] [PMC free article] [PubMed] [Google Scholar]
7.Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, Yuan L, et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med. 2009;15(7):750–6. 10.1038/nm.1983 [DOI] [PMC free article] [PubMed] [Google Scholar]
8.Wang Y, Zhang H, Chen Y, Sun Y, Yang F, Yu W, et al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell. 2009;138(4):660–72. Epub 2009/08/26. 10.1016/j.cell.2009.05.050 . [DOI] [PubMed] [Google Scholar]
9.Feng Z, Yao Y, Zhou C, Chen F, Wu F, Wei L, et al. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia. J Hematol Oncol. 2016;9:24 Epub 2016/03/15. 10.1186/s13045-016-0252-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
10.Alsaquer SF, Tashkandi MM, Kartha VK, Yang Y-T, Alkheriji Y, Salama A, et al. Inhibition of lsd1 epigenetically attenuates oral cancer growth and metastasis. Oncotarget. 2017;8(43):73372–86. Epub 07/27/17. 10.18632/oncotarget.19637 PubMed Central PMCID: PMC5650269. [DOI] [PMC free article] [PubMed] [Google Scholar]
11.Fang J, Landersdorfer CB, Cirincione B, Jusko WJ. Study reanalysis using a mechanism-based pharmacokinetic/pharmacodynamic model of pramlintide in subjects with type 1 diabetes. AAPS J. 2013;15(1):15–29. 10.1208/s12248-012-9409-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
12.Sankar S, Theisen ER, Bearss J, Mulvihill T, Hoffman LM, Sorna V, et al. Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. Clin Cancer Res. 2014;20(17):4584–97. 10.1158/1078-0432.CCR-14-0072 [DOI] [PMC free article] [PubMed] [Google Scholar]
13.McGrath JP, Williamson KE, Balasubramanian S, Odate S, Arora S, Hatton C, et al. Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes. Cancer Res. 2016;76(7):1975–88. Epub 2016/02/04. 10.1158/0008-5472.CAN-15-2333 . [DOI] [PubMed] [Google Scholar]
14.Sehrawat A, Gao L, Wang Y, Bankhead A, 3rd, McWeeney SK, King CJ, et al. LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018;115(18):E4179–E88. Epub 2018/03/28. 10.1073/pnas.1719168115 [DOI] [PMC free article] [PubMed] [Google Scholar]
15.Mohammad HP, Smitheman KN, Kamat CD, Soong D, Federowicz KE, Van Aller GS, et al. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell. 2015;28(1):57–69. Epub 2015/07/16. 10.1016/j.ccell.2015.06.002 . [DOI] [PubMed] [Google Scholar]
16.Maes T, Mascaro C, Tirapu I, Estiarte A, Ciceri F, Lunardi S, et al. ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia. Cancer Cell. 2018;33(3):495–511 e12. Epub 2018/03/06. 10.1016/j.ccell.2018.02.002 . [DOI] [PubMed] [Google Scholar]
17.Romo-Morales A, Aladowicz E, Blagg J, Gatz SA, Shipley JM. Catalytic inhibition of KDM1A in Ewing sarcoma is insufficient as a therapeutic strategy. Pediatr Blood Cancer. 2019;66(9):e27888 Epub 2019/06/18. 10.1002/pbc.27888 . [DOI] [PubMed] [Google Scholar]
18.Sonnemann J, Zimmerman M, Marx C, Ebert F, Becker S, Lauterjung M-L, et al. LSDI (KMDIA)-independent effects of the LSD1 inhibitor SP2509 in cancer cells. British Journal of Haemetology. 2018;183:491–524. Epub 12/03/17. 10.1111/bjh.14983 PubMed Central PMCID: PMC 29205263 [DOI] [PubMed] [Google Scholar]
19.Sonnemann J, Dreyer L, Hartwig M, Palani CD, Hong LTT, Klier U, et al. Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing’s sarcoma cells. Journal of Cancer Research and Clinical Oncology. 2007;133(11):847–58. 10.1007/s00432-007-0227-8 [DOI] [PubMed] [Google Scholar]
20.Shi YJ, Matson C, Lan F, Iwase S, Baba T, Shi Y. Regulation of LSD1 histone demethylase activity by its associated factors. Mol Cell. 2005;19(6):857–64. Epub 2005/09/06. 10.1016/j.molcel.2005.08.027 . [DOI] [PubMed] [Google Scholar]
21.Thomas S, Aggarwal R, Jahan T, Ryan C, Troung T, Cripps AM, et al. A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. Ann Oncol. 2016;27(5):947–52. Epub 2016/02/24. 10.1093/annonc/mdw044 [DOI] [PMC free article] [PubMed] [Google Scholar]
22.Cassier PA, Lefranc A, Amela EY, Chevreau C, Bui BN, Lecesne A, et al. A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group. Br J Cancer. 2013;109(4):909–14. Epub 2013/08/08. 10.1038/bjc.2013.442 [DOI] [PMC free article] [PubMed] [Google Scholar]
23.Kahen E, Yu D, Harrison DJ, Clark J, Hingorani P, Cubitt CL, et al. Identification of clinically achievable combination therapies in childhood rhabdomyosarcoma. Cancer Chemother Pharmacol. 2016;78(2):313–23. Epub 2016/06/22. 10.1007/s00280-016-3077-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
24.Yu D, Kahen E, Cubitt CL, McGuire J, Kreahling J, Lee J, et al. Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma. Sci Rep. 2015;5:16991 Epub 2015/11/26. 10.1038/srep16991 [DOI] [PMC free article] [PubMed] [Google Scholar]
25.Goldsby RE, Fan TM, Villaluna D, Wagner LM, Isakoff MS, Meyer J, et al. Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Eur J Cancer. 2013;49(10):2384–91. Epub 2013/05/15. 10.1016/j.ejca.2013.03.018 [DOI] [PMC free article] [PubMed] [Google Scholar]
26.Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23(9):2004–11. Epub 2005/03/19. 10.1200/JCO.2005.06.031 . [DOI] [PubMed] [Google Scholar]
27.Pishas KI, Drenberg CD, Taslim C, Theisen ER, Johnson KM, Saund RS, et al. Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response. Molecular Cancer Therapeutics. 2018;17(9):1902–16. 10.1158/1535-7163.MCT-18-0373 [DOI] [PMC free article] [PubMed] [Google Scholar]
28.El-Najjar N, Ketola RA, Nissila T, Mauriala T, Antopolsky M, Janis J, et al. Impact of protein binding on the analytical detectability and anticancer activity of thymoquinone. J Chem Biol. 2011;4(3):97–107. Epub 2012/01/10. 10.1007/s12154-010-0052-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
29.Chou T-C. Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies. Pharmacological Reviews. 2006;58(3):621–81. 10.1124/pr.58.3.10 [DOI] [PubMed] [Google Scholar]
30.Wagner LM. Fifteen years of irinotecan therapy for pediatric sarcoma: where to next? Clin Sarcoma Res. 2015;5:20 Epub 2015/09/01. 10.1186/s13569-015-0035-x [DOI] [PMC free article] [PubMed] [Google Scholar]
31.Palmerini E, Jones RL, Setola E, Picci P, Marchesi E, Luksch R, et al. Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients. Acta Oncol. 2018;57(7):958–64. Epub 2018/03/14. 10.1080/0284186X.2018.1449250 . [DOI] [PubMed] [Google Scholar]
32.Crompton BD, Stewart C, Taylor-Weiner A, Alexe G, Kurek KC, Calicchio ML, et al. The Genomic Landscape of Pediatric Ewing Sarcoma. Cancer Discovery. 2014;4(11):1326–41. 10.1158/2159-8290.CD-13-1037 [DOI] [PubMed] [Google Scholar]
33.Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012;30(33):4148–54. 10.1200/JCO.2011.41.5703 [DOI] [PMC free article] [PubMed] [Google Scholar]
34.Reed DR, Hayashi M, Wagner L, Binitie O, Steppan DA, Brohl AS, et al. Treatment pathway of bone sarcoma in children, adolescents, and young adults. Cancer. 2017;123(12):2206–18. 10.1002/cncr.30589 [DOI] [PMC free article] [PubMed] [Google Scholar]
35.Rudolph T, Yonezawa M, Lein S, Heidrich K, Kubicek S, Schafer C, et al. Heterochromatin formation in Drosophila is initiated through active removal of H3K4 methylation by the LSD1 homolog SU(VAR)3-3. Mol Cell. 2007;26(1):103–15. Epub 2007/04/17. 10.1016/j.molcel.2007.02.025 . [DOI] [PubMed] [Google Scholar]
36.Hayami S, Kelly JD, Cho HS, Yoshimatsu M, Unoki M, Tsunoda T, et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer. 2011;128(3):574–86. Epub 2010/03/25. 10.1002/ijc.25349 . [DOI] [PubMed] [Google Scholar]
37.Zöllner SK, Selvanathan SP, Graham GT, Commins RMT, Hong SH, Moseley E, et al. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G2-M cell cycle arrest and enhanced vincristine sensitivity in Ewing’s sarcoma. Science Signaling. 2017;10(499). 10.1126/scisignal.aam8429 [DOI] [PMC free article] [PubMed] [Google Scholar]
38.May WA, Grigoryan RS, Keshelava N, Cabral DJ, Christensen LL, Jenabi J, et al. Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines. PLoS One. 2013;8(12):e80060 10.1371/journal.pone.0080060 [DOI] [PMC free article] [PubMed] [Google Scholar]
39.Franzetti GA, Laud-Duval K, van der Ent W, Brisac A, Irondelle M, Aubert S, et al. Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma cells. Oncogene. 2017;36(25):3505–14. Epub 2017/01/31. 10.1038/onc.2016.498 [DOI] [PMC free article] [PubMed] [Google Scholar]
40.Gupta S, Weston A, Bearrs J, Thode T, Neiss A, Soldi R, et al. Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells. Prostate Cancer Prostatic Dis. 2016;19(4):349–57. Epub 2016/06/29. 10.1038/pcan.2016.21 [DOI] [PMC free article] [PubMed] [Google Scholar]
41.Sato T, Cesaroni M, Chung W, Panjarian S, Tran A, Madzo J, et al. Transcriptional Selectivity of Epigenetic Therapy in Cancer. Cancer Research. 2017;77(2):470–81. 10.1158/0008-5472.CAN-16-0834 [DOI] [PMC free article] [PubMed] [Google Scholar]
42.Haydn T, Metzger E, Schuele R, Fulda S. Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells. Cell Death Dis. 2017;8(6):e2879 Epub 2017/06/16. 10.1038/cddis.2017.239 [DOI] [PMC free article] [PubMed] [Google Scholar]
43.Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SG, Liu K, et al. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia. 2014;28(11):2155–64. Epub 2014/04/05. 10.1038/leu.2014.119 [DOI] [PMC free article] [PubMed] [Google Scholar]
44.Kalin JH, Wu M, Gomez AV, Song Y, Das J, Hayward D, et al. Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nat Commun. 2018;9(1):53 Epub 2018/01/06. 10.1038/s41467-017-02242-4 [DOI] [PMC free article] [PubMed] [Google Scholar]

PLoS One. doi: 10.1371/journal.pone.0222228.r001

Decision Letter 0

Arun Rishi

29 Jul 2019

PONE-D-19-18074

Small Molecule Inhibition of Lysine-Specific Demethylase 1 (LSD1) and Histone Deactylase (HDAC) Alone and in Combination in Ewing Sarcoma Cell Lines

PLOS ONE

Dear Dr Reed,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Although both the reviewers indicated an overall enthusiasm for the studies, it was however felt that further discussion and justifications/rationale for choosing certain compounds and their combination studies would be necessary.

We would appreciate receiving your revised manuscript by Sep 12 2019 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.
A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.
An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Arun Rishi, Ph.D.

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please provide additional information about each of the cell lines used in this work, including history, culture conditions and any quality control testing procedures (authentication, characterisation, and mycoplasma testing). For more information, please see http://journals.plos.org/plosone/s/submission-guidelines#loc-cell-lines.

3. Our staff editors have determined that your manuscript is likely within the scope of our Targeted Anticancer Therapies and Precision Medicine Call for Papers. This editorial initiative is headed by a team of Guest Editors for PLOS ONE: Andrew Cherniack, Anette Duensing, Steven Gray, Sunil Krishnan, Chandan Kumar-Sinha and Gayle Woloschak. The Collection will encompass a diverse range of research articles about the identification and classification of driver genes and somatic alterations, target and drug discovery, mechanisms of drug resistance, and early detection and screening. Additional information can be found on our announcement page: https://collections.plos.org/s/targeted-anticancer-therapies.

If you would like your manuscript to be considered for this collection, please let us know in your cover letter and we will ensure that your paper is treated as if you were responding to this call. If you would prefer to remove your manuscript from collection consideration, please specify this in the cover letter.

4. Thank you for stating the following in the Financial Disclosure section: "This study was generously supported by the National Pediatric Cancer Foundation (www.nationalpcf.org). This work has been supported in part by the Translational Research Core at the H. Lee Moffitt Cancer Center & Research Institute, a NCI designated Comprehensive Cancer Center (P30-CA076292)."

We note that one or more of the authors are employed by a commercial company: 'Sunshine Lab LLC'.

a) Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

“The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.”

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

b) Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests) . If this adherence statement is not accurate and there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The purpose of this study by Welch et al., was to define clinical agents that synergize with the LSD1 inhibitor SP2509 in Ewing sarcoma, an aggressive childhood cancer which has seen limited improvement in overall survival since the introduction of chemotherapy >50 years ago. The authors tested 7 clinically utilized chemotherapeutic agents in four different Ewing sarcoma cell lines with varying KDM1A expression levels and TP53/STAG2 mutational status. Order of addition of second line conventional combination therapy agents were also tested with the addition of SP2509.

The authors should be commended on several factors including their reproducible and high throughput method for exploring antitumor effects of combinations of therapies at clinically achievable concentrations. All concentrations used in experiments were well below observed maximal plasma concentrations. In addition, it is refreshing to see that the authors used active metabolites of cyclophosphamide, irinotecan, and temozolomide which is frequently overlooked. As all experimental considerations for combination therapy were developed and conducted with the end thought of rapid translation into current LSD1 trials, data presented in this manuscript has the potential to significantly improve the survival outcomes for Ewing sarcoma patients as well as demonstrating to the scientific community how synergy experiments should be conducted. The data is technically sound with multiple replicates and each conclusion is supported by the data presented.

Minor comments for consideration

Introduction

1) As synergism with SP2509 was the main premise for this study, the authors should explain why SP2509 was chosen over other LSD1 inhibitors (GSK2879552 and ORY-1001). It would be helpful to state in the introduction that SP2509 is currently in Phase I clinical testing for Ewing sarcoma patients (NCT03600649) and that Ewing sarcoma cell lines are resistant to reversible inhibitors (Romo‐Morales et al., Pediatric Blood & Cancer, 2019).

2) To prevent confusion, it should be noted in the text that SP2509 was formally known as HCI2509.

Results section

1) Minor concern for this study was the decision to use Romidepsin which is only clinically approved for T-cell lymphoma. Considering the Phase 2 clinical trial of Romidepsin (NCT00112463) failed in 40 patients with metastatic or unresectable sarcoma, what is the likely hood of this HDAC inhibitor being chosen for further study in solid tumors?

2) Reference is required for the following statement “HDAC1 and HDAC2 inhibitor romidepsin and the reversible LSD1 inhibitor SP2509, were selected based on their respective targets in the NuRD complex” Lines 171-172.

3) Figure 1: Viability time point should be listed in the figure legend ie 24 or 72hr treatment. Image quality is also quite poor and should be corrected.

4) The authors state on Line 200 that “SP2509 showed synergy with all drugs apart from vincristine”. Can the authors postulate why? Is anything known for the cell lines in terms of previous chemotherapy treatment and does this explain sensitivity/resistance to the agents tested?

5) On lines 285-286, the authors elude to sensitivity of drugs may “simply be due to differences in doubling times”. This is quite possible considering the doubling times for the majority of cell lines ranges from 21-25hrs except for RDES (60hrs) (May et al., PLOS ONE, 2013). The authors should include doubling rates for each cell line in Table 1.

6) Is there any correlation between sensitivity to SP2509 and the other chemotherapeutic agents tested?

7) With all the different dosing schedules and agents, it was quite difficult throughout the manuscript to track which agents were synergistic over multiple cell lines. It would be nice to present a final table/figure summarizing which agents where synergistic across all four Ewing sarcoma cell lines and dosing schedules.

8) Minor notes, gene names should be in italics eg Line 275 TP53 and STAG2.

Discussion

1) Do the authors know whether SP2509 and SP2577 have similar IC50 values? This will have implications as to whether their synergistic findings can be replicated with SP2577 in clinical settings.

2) Although not used for clinical settings in Ewing sarcoma, SP2509 has been shown to synergise with docetaxel in prostate cancer (Gupta et al., 2016). This study should be referenced.

3) The dosing model presented in Supplementary Figure 2 is quite interesting and should be moved to the main text.

Reviewer #2: This study describes in vitro 2D analyses of cell viability for drug combination indices of an HDAC and an LSD1 inhibitor combined with standard chemotherapies used for treatment of ewing sarcomas. Overall the experiments appear well executed and described.

Although this is clearly not a mechanistic paper, the authors should better consider and discuss

i. the reasons supporting their hypothesis “that agents that interact with components of the NuRD complex would work synergistically with agents already utilized in the treatment of ES”.

ii. the rationale behind the choice of HDAC and LSD1 inhibitors including recent comments about how SP2509 may work (PMID: 29205263 PMID:31207107)

iii. possible mechanistic explanations for the results of the most and least synergistic combinations in different cell lines. For example it has been published that cells with low EWS-FLI1 expression are less proliferative PMID:28135250. Does this impact on the sensitivity of the agents used? The mechanism of action of some chemotherapeutic agents used depends on rapid cell cycling, e.g. SN-38. Can this be considered in light of A673’s relative insensitivity to topoisomerases? comments/considerations around reversal of insensitivity of

iv. the importance of scheduling. They only do one sequential experiment in which the order of drugs is changed.

v. the importance around time of treatment. Activity is reported at 72hours, however drugs targeting epigenetic modifying enzymes have been shown to benefit from prolonged exposure (EZH2 inhibitors in lymphoma). Longer-term assays could be useful to achieve maximal drug efficacy and therefore give a broader overview of their activity in combination with chemotherapeutic agents.

vi. Given the previous effects of LSD1 on migration (PMID:18381423) and the potential clinical significance of this phenotype, why was this not assessed or discussed?

Minor comments:

Page 3 line 44 sentence unclear – most commonly t(11;22)(q24;12) between the amino … – “12” should be q12 is missing and that fuses would be better than “between”

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2019 Sep 24;14(9):e0222228. doi: 10.1371/journal.pone.0222228.r002

Author response to Decision Letter 0

8 Aug 2019

August 8, 2019

Dear Editors:

Please find our revised manuscript, “Small Molecule Inhibition of Lysine-Specific Demethylase 1 (LSD1) Alone and in Combination in Ewing Sarcoma Cell Lines” by Darcy Welch and Elliot Kahen et al., which we would like to submit for consideration of publication as an original research article in PLOS One.

Thank you for the favorable review. We would indeed like to accept the offer of having this considered for the Targeted Anticancer Therapies and Precision Medicine Call for Papers as we agree it is within the scope of this collection.

Also to clarify, there is no Sunshine Lab, LLC or commercial company involved in this research. All work done, and all authors are employees of an Academic Cancer Center.

Below is a point by point response to the Reviewers’ comments.

Thank you for receiving our revised manuscript and considering it for review. We appreciate your time and look forward to your response.

Damon Reed, M.D.,

Associate Member, Department of Interdisciplinary Cancer Management and Sarcoma Departments

Director of Adolescent and Young Adult Program

Moffitt Cancer Center and Research Institute

12902 Magnolia Drive, Tampa, Florida 33612.

Phone: 813-745-3242, Fax: 813-745-8337

Email: damon.reed@moffitt.org

Editor Comments:

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

-We have ensured style requirement compliance with this version.

-We have added this detail to the methods section.

-We have noted above that we would like this article to be considered for this call for papers. Thank you for this opportunity.

We note that one or more of the authors are employed by a commercial company: 'Sunshine Lab LLC'.

-Sorry for the confusion. The Sunshine Lab is not an LLC, nor a commercial company. The Sunshine Lab is a term for the academic lab within Moffitt Cancer Center and all lab members are fully employed by Moffitt Cancer Center. It is analogous to naming a lab after a donor. The National Pediatric Cancer Foundation, a nonprofit and funder of the lab, does not have any say regarding the research performed in the lab.

Reviewer Comments:

Reviewer 1: Minor comments for consideration

Introduction

-Thank you for this recent reference, new since our submission (Line 65-72).

2) To prevent confusion, it should be noted in the text that SP2509 was formally known as HCI2509.

-Thank you and agree. We have clarified this.

Results section

-We agree that HDAC inhibitors have a poor track record in sarcomas when given at hematologic malignancy doses and schedules. Specific to this project, the NuRD complex may contain HDAC1 and/or 2 and we were both curious as to whether or not inhibition of HDACs would phenotypically copy LSD1 inhibition. We also anticipated the question of whether or not HDAC and LSD1 play similar roles in this complexes general function. We believe that our results show romidepsin is a promising agent for ES treatment but SP2509 is a better candidate due to less antagonism across agents. Additionally we agree with the pragmatic point of the reviewer that HDAC inhibitors are unlikely to be studied in sarcomas. Since thresholds of efficacy are much lower in vitro than in clinical trials, we wanted to explore if romidepsin had any activity worthy of further mechanistic studies. We modified the manuscript to include our reasoning in selecting romidepsin (Lines 74-77)

-We have added the reference as well as adding additional information on our reasoning for selection in the introduction (Line 197).

3) Figure 1: Viability time point should be listed in the figure legend ie 24 or 72hr treatment. Image quality is also quite poor and should be corrected.

- We are sorry about the final image quality which we’ve learned is due to the generated pdf having a process that turned 600dpi TIFF files into jpegs. We have found that in the upper right of each figure is a link that can be clicked to quickly download the figure in the high res which was indeed submitted and will be in the final publication. The figure legend has been amended with the appropriate 72hr treatment.

-We appreciate the suggestion to comment further on this finding. We have added a sentence in the discussion postulating why (Line 362-377). In terms of prior therapy for the cell lines, TC-71 was derived post-chemo from a biopsy of a locally recurrent tumor; TC-32 was derived post-chemo; A673 is unknown; RD-ES was derived from a primary osseous of the humerus. This info has been added to the manuscript and briefly discussed.

-Very helpful and we agree. We have added both the doubling time and the suggested reference.

6) Is there any correlation between sensitivity to SP2509 and the other chemotherapeutic agents tested?

- The strongest correlation occurs between SP2509 and DNA damaging agents. This has been added to the manuscript along with Figure 4 and a possible explanation of the mechanism (Lines 354-358).

-A table of the top concentrations across all 4 cell lines has been added to the supplementary tables (S3 Table).

8) Minor notes, gene names should be in italics eg Line 275 TP53 and STAG2.

-Thank you again, this has been fixed.

Discussion

1) Do the authors know whether SP2509 and SP2577 have similar IC50 values? This will have implications as to whether their synergistic findings can be replicated with SP2577 in clinical settings.

- Since SP2577 involves company collaboration and review and we have limits on being able to publish data with the clinical compound, we have not included this agent in this report. We indeed tested both SP2577 and SP2509. We found that the IC50’s were similar for both compounds. SP2577 was slightly higher but on the same order of magnitude as SP2509. The company did not provide any financial support nor did they have any say in which experiments were performed.

2) Although not used for clinical settings in Ewing sarcoma, SP2509 has been shown to synergise with docetaxel in prostate cancer (Gupta et al., 2016). This study should be referenced.

-We have added this reference and comment (Lines 375-377).

3) The dosing model presented in Supplementary Figure 2 is quite interesting and should be moved to the main text.

-Thank you. We struggled with including this in the main text versus supplemental but are happy to include this in the main body of the manuscript. It is now Fig 5.

Although this is clearly not a mechanistic paper, the authors should better consider and discuss

-We agree that this is not a mechanistic paper and more of a phenotypic paper regarding responses to agents. We do thank the reviewer for these strong comments and we hope our responses strengthen the interpretation and contextualization of the data. We agree there are many directions to go in terms of assays, schedules and time points. There are always more experiments to do and questions than answers. We are not prepared to do additional order of addition assays, or other experiments and it does not appear that this is being asked by the reviewer. We do add comments with this revision to help get these good points into the discussion to suggest next steps and to update the citations with emerging data regarding LSD1 and Ewing sarcoma.

i. the reasons supporting their hypothesis “that agents that interact with components of the NuRD complex would work synergistically with agents already utilized in the treatment of ES”.

-We have added to the introduction that the fusion oncoprotein is considered to be the driver of Ewing sarcoma and that the rationale for targeting both the fusion protein activity along with agents known to provide clinical benefit seems like a promising next step in treating Ewing sarcoma. It is currently unclear how the standard agents affect the fusion protein function.

ii. the rationale behind the choice of HDAC and LSD1 inhibitors including recent comments about how SP2509 may work (PMID: 29205263 PMID:31207107)

-We added comments and references in the introduction and discussion on our rationale in addition to reviewer #1’s comment and feel we have addressed this point up to current knowledge (Lines 65-77).

-We thank the reviewer for this. The comment again we feel is addressed by responses above to reviewer #1’s comment. Franzetti et al. has been added to the manuscript and we agree the results are intriguing (Lines 363-370).

iv. the importance of scheduling. They only do one sequential experiment in which the order of drugs is changed.

- Our initial experiment did not show significant differences in the order of addition so we decided not to investigate further. We comment that future studies exploring dose and schedule are warranted.

-We added a comment as we do agree with this point (Line 415).

vi. Given the previous effects of LSD1 on migration (PMID:18381423) and the potential clinical significance of this phenotype, why was this not assessed or discussed?

-While migration assays are employed at times, we are not sure how drug effects on the migratory phenotype are applicable in the context of the performed experiments and tend to favor cell viability as the endpoint for these first screens of activity. It is difficult to imagine clinical activity from an agent that affects cell migration over viability. While we do believe migration, environment, metastases are indeed aspects of tumor biology that are tremendously important, the scope of this project was to measure viability towards translation to clinic.

Minor comments:

Page 3 line 44 sentence unclear – most commonly t(11;22)(q24;12) between the amino … – “12” should be q12 is missing and that fuses would be better than “between”

-We have fixed this, thank you.

PLoS One. doi: 10.1371/journal.pone.0222228.r003

Decision Letter 1

Arun Rishi

26 Aug 2019

[EXSCINDED]

Small Molecule Inhibition of Lysine-Specific Demethylase 1 (LSD1) and Histone Deactylase (HDAC) Alone and in Combination in Ewing Sarcoma Cell Lines

PONE-D-19-18074R1

Dear Dr. Reed,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

With kind regards,

Arun Rishi, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: N/A

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Reviewer #1: (No Response)

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

PLoS One. doi: 10.1371/journal.pone.0222228.r004

Acceptance letter

Arun Rishi

9 Sep 2019

PONE-D-19-18074R1

Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines

Dear Dr. Reed:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

For any other questions or concerns, please email plosone@plos.org.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof Arun Rishi

Academic Editor

PLOS ONE

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

S1 Fig. All order of addition results including two-drug, three-drug, and four-drug combinations as discussed in Fig 3.

a) A673 (2250 cells), b) TC32 (4500 cells), c) A673 (4500 cells).

(TIF)

Click here for additional data file.^{(3.4MB, tif)}

S1 Table

A) Average IC₅₀ ± standard error. B) IC₅₀ ± standard error as a % of Cmax. C) IC₅₀ ± standard error with conditional formatting indicating % Cmax.

(TIFF)

Click here for additional data file.^{(685.4KB, tiff)}

S2 Table. Full table of two-drug combinations.

(DOCX)

Click here for additional data file.^{(377.7KB, docx)}

S3 Table. Top combination treatment regimens based on a combination of FA and CI.

(TIF)

Click here for additional data file.^{(5.4MB, tif)}

Data Availability Statement

All relevant data are within the manuscript and its Supporting Information files.

[pone.0222228.ref001] 1.Gorlick R, Janeway K, Lessnick S, Randall RL, Marina N, Committee COGBT. Children's Oncology Group's 2013 blueprint for research: bone tumors. Pediatr Blood Cancer. 2013;60(6):1009–15. 10.1002/pbc.24429 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0222228.ref002] 2.Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992;359(6391):162–5. 10.1038/359162a0 [DOI] [PubMed] [Google Scholar]

[pone.0222228.ref003] 3.Sankar S, Bell R, Stephens B, Zhuo R, Sharma S, Bearss DJ, et al. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. Oncogene. 2013;32(42):5089–100. 10.1038/onc.2012.525 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0222228.ref004] 4.Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, et al. The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genet. 2014;10(7):e1004475 10.1371/journal.pgen.1004475 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0222228.ref005] 5.Crompton BD, Stewart C, Taylor-Weiner A, Alexe G, Kurek KC, Calicchio ML, et al. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov. 2014;4(11):1326–41. 10.1158/2159-8290.CD-13-1037 . [DOI] [PubMed] [Google Scholar]

[pone.0222228.ref006] 6.Tirode F, Surdez D, Ma X, Parker M, Le Deley MC, Bahrami A, et al. Genomic Landscape of Ewing Sarcoma Defines an Aggressive Subtype with Co-Association of STAG2 and TP53 Mutations. Cancer Discovery. 2014;4(11):1342–53. 10.1158/2159-8290.CD-14-0622 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0222228.ref007] 7.Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, Yuan L, et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med. 2009;15(7):750–6. 10.1038/nm.1983 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0222228.ref008] 8.Wang Y, Zhang H, Chen Y, Sun Y, Yang F, Yu W, et al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell. 2009;138(4):660–72. Epub 2009/08/26. 10.1016/j.cell.2009.05.050 . [DOI] [PubMed] [Google Scholar]

[pone.0222228.ref009] 9.Feng Z, Yao Y, Zhou C, Chen F, Wu F, Wei L, et al. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia. J Hematol Oncol. 2016;9:24 Epub 2016/03/15. 10.1186/s13045-016-0252-7 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0222228.ref010] 10.Alsaquer SF, Tashkandi MM, Kartha VK, Yang Y-T, Alkheriji Y, Salama A, et al. Inhibition of lsd1 epigenetically attenuates oral cancer growth and metastasis. Oncotarget. 2017;8(43):73372–86. Epub 07/27/17. 10.18632/oncotarget.19637 PubMed Central PMCID: PMC5650269. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0222228.ref011] 11.Fang J, Landersdorfer CB, Cirincione B, Jusko WJ. Study reanalysis using a mechanism-based pharmacokinetic/pharmacodynamic model of pramlintide in subjects with type 1 diabetes. AAPS J. 2013;15(1):15–29. 10.1208/s12248-012-9409-7 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0222228.ref012] 12.Sankar S, Theisen ER, Bearss J, Mulvihill T, Hoffman LM, Sorna V, et al. Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. Clin Cancer Res. 2014;20(17):4584–97. 10.1158/1078-0432.CCR-14-0072 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0222228.ref013] 13.McGrath JP, Williamson KE, Balasubramanian S, Odate S, Arora S, Hatton C, et al. Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes. Cancer Res. 2016;76(7):1975–88. Epub 2016/02/04. 10.1158/0008-5472.CAN-15-2333 . [DOI] [PubMed] [Google Scholar]

[pone.0222228.ref014] 14.Sehrawat A, Gao L, Wang Y, Bankhead A, 3rd, McWeeney SK, King CJ, et al. LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018;115(18):E4179–E88. Epub 2018/03/28. 10.1073/pnas.1719168115 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0222228.ref015] 15.Mohammad HP, Smitheman KN, Kamat CD, Soong D, Federowicz KE, Van Aller GS, et al. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell. 2015;28(1):57–69. Epub 2015/07/16. 10.1016/j.ccell.2015.06.002 . [DOI] [PubMed] [Google Scholar]

[pone.0222228.ref016] 16.Maes T, Mascaro C, Tirapu I, Estiarte A, Ciceri F, Lunardi S, et al. ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia. Cancer Cell. 2018;33(3):495–511 e12. Epub 2018/03/06. 10.1016/j.ccell.2018.02.002 . [DOI] [PubMed] [Google Scholar]

[pone.0222228.ref017] 17.Romo-Morales A, Aladowicz E, Blagg J, Gatz SA, Shipley JM. Catalytic inhibition of KDM1A in Ewing sarcoma is insufficient as a therapeutic strategy. Pediatr Blood Cancer. 2019;66(9):e27888 Epub 2019/06/18. 10.1002/pbc.27888 . [DOI] [PubMed] [Google Scholar]

[pone.0222228.ref018] 18.Sonnemann J, Zimmerman M, Marx C, Ebert F, Becker S, Lauterjung M-L, et al. LSDI (KMDIA)-independent effects of the LSD1 inhibitor SP2509 in cancer cells. British Journal of Haemetology. 2018;183:491–524. Epub 12/03/17. 10.1111/bjh.14983 PubMed Central PMCID: PMC 29205263 [DOI] [PubMed] [Google Scholar]

[pone.0222228.ref019] 19.Sonnemann J, Dreyer L, Hartwig M, Palani CD, Hong LTT, Klier U, et al. Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing’s sarcoma cells. Journal of Cancer Research and Clinical Oncology. 2007;133(11):847–58. 10.1007/s00432-007-0227-8 [DOI] [PubMed] [Google Scholar]

[pone.0222228.ref020] 20.Shi YJ, Matson C, Lan F, Iwase S, Baba T, Shi Y. Regulation of LSD1 histone demethylase activity by its associated factors. Mol Cell. 2005;19(6):857–64. Epub 2005/09/06. 10.1016/j.molcel.2005.08.027 . [DOI] [PubMed] [Google Scholar]

[pone.0222228.ref021] 21.Thomas S, Aggarwal R, Jahan T, Ryan C, Troung T, Cripps AM, et al. A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. Ann Oncol. 2016;27(5):947–52. Epub 2016/02/24. 10.1093/annonc/mdw044 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0222228.ref022] 22.Cassier PA, Lefranc A, Amela EY, Chevreau C, Bui BN, Lecesne A, et al. A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group. Br J Cancer. 2013;109(4):909–14. Epub 2013/08/08. 10.1038/bjc.2013.442 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0222228.ref023] 23.Kahen E, Yu D, Harrison DJ, Clark J, Hingorani P, Cubitt CL, et al. Identification of clinically achievable combination therapies in childhood rhabdomyosarcoma. Cancer Chemother Pharmacol. 2016;78(2):313–23. Epub 2016/06/22. 10.1007/s00280-016-3077-8 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0222228.ref024] 24.Yu D, Kahen E, Cubitt CL, McGuire J, Kreahling J, Lee J, et al. Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma. Sci Rep. 2015;5:16991 Epub 2015/11/26. 10.1038/srep16991 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0222228.ref025] 25.Goldsby RE, Fan TM, Villaluna D, Wagner LM, Isakoff MS, Meyer J, et al. Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Eur J Cancer. 2013;49(10):2384–91. Epub 2013/05/15. 10.1016/j.ejca.2013.03.018 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0222228.ref026] 26.Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23(9):2004–11. Epub 2005/03/19. 10.1200/JCO.2005.06.031 . [DOI] [PubMed] [Google Scholar]

[pone.0222228.ref027] 27.Pishas KI, Drenberg CD, Taslim C, Theisen ER, Johnson KM, Saund RS, et al. Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response. Molecular Cancer Therapeutics. 2018;17(9):1902–16. 10.1158/1535-7163.MCT-18-0373 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0222228.ref028] 28.El-Najjar N, Ketola RA, Nissila T, Mauriala T, Antopolsky M, Janis J, et al. Impact of protein binding on the analytical detectability and anticancer activity of thymoquinone. J Chem Biol. 2011;4(3):97–107. Epub 2012/01/10. 10.1007/s12154-010-0052-4 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0222228.ref029] 29.Chou T-C. Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies. Pharmacological Reviews. 2006;58(3):621–81. 10.1124/pr.58.3.10 [DOI] [PubMed] [Google Scholar]

[pone.0222228.ref030] 30.Wagner LM. Fifteen years of irinotecan therapy for pediatric sarcoma: where to next? Clin Sarcoma Res. 2015;5:20 Epub 2015/09/01. 10.1186/s13569-015-0035-x [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0222228.ref031] 31.Palmerini E, Jones RL, Setola E, Picci P, Marchesi E, Luksch R, et al. Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients. Acta Oncol. 2018;57(7):958–64. Epub 2018/03/14. 10.1080/0284186X.2018.1449250 . [DOI] [PubMed] [Google Scholar]

[pone.0222228.ref032] 32.Crompton BD, Stewart C, Taylor-Weiner A, Alexe G, Kurek KC, Calicchio ML, et al. The Genomic Landscape of Pediatric Ewing Sarcoma. Cancer Discovery. 2014;4(11):1326–41. 10.1158/2159-8290.CD-13-1037 [DOI] [PubMed] [Google Scholar]

[pone.0222228.ref033] 33.Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012;30(33):4148–54. 10.1200/JCO.2011.41.5703 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0222228.ref034] 34.Reed DR, Hayashi M, Wagner L, Binitie O, Steppan DA, Brohl AS, et al. Treatment pathway of bone sarcoma in children, adolescents, and young adults. Cancer. 2017;123(12):2206–18. 10.1002/cncr.30589 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0222228.ref035] 35.Rudolph T, Yonezawa M, Lein S, Heidrich K, Kubicek S, Schafer C, et al. Heterochromatin formation in Drosophila is initiated through active removal of H3K4 methylation by the LSD1 homolog SU(VAR)3-3. Mol Cell. 2007;26(1):103–15. Epub 2007/04/17. 10.1016/j.molcel.2007.02.025 . [DOI] [PubMed] [Google Scholar]

[pone.0222228.ref036] 36.Hayami S, Kelly JD, Cho HS, Yoshimatsu M, Unoki M, Tsunoda T, et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer. 2011;128(3):574–86. Epub 2010/03/25. 10.1002/ijc.25349 . [DOI] [PubMed] [Google Scholar]

[pone.0222228.ref037] 37.Zöllner SK, Selvanathan SP, Graham GT, Commins RMT, Hong SH, Moseley E, et al. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G2-M cell cycle arrest and enhanced vincristine sensitivity in Ewing’s sarcoma. Science Signaling. 2017;10(499). 10.1126/scisignal.aam8429 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0222228.ref038] 38.May WA, Grigoryan RS, Keshelava N, Cabral DJ, Christensen LL, Jenabi J, et al. Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines. PLoS One. 2013;8(12):e80060 10.1371/journal.pone.0080060 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0222228.ref039] 39.Franzetti GA, Laud-Duval K, van der Ent W, Brisac A, Irondelle M, Aubert S, et al. Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma cells. Oncogene. 2017;36(25):3505–14. Epub 2017/01/31. 10.1038/onc.2016.498 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0222228.ref040] 40.Gupta S, Weston A, Bearrs J, Thode T, Neiss A, Soldi R, et al. Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells. Prostate Cancer Prostatic Dis. 2016;19(4):349–57. Epub 2016/06/29. 10.1038/pcan.2016.21 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0222228.ref041] 41.Sato T, Cesaroni M, Chung W, Panjarian S, Tran A, Madzo J, et al. Transcriptional Selectivity of Epigenetic Therapy in Cancer. Cancer Research. 2017;77(2):470–81. 10.1158/0008-5472.CAN-16-0834 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0222228.ref042] 42.Haydn T, Metzger E, Schuele R, Fulda S. Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells. Cell Death Dis. 2017;8(6):e2879 Epub 2017/06/16. 10.1038/cddis.2017.239 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0222228.ref043] 43.Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SG, Liu K, et al. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia. 2014;28(11):2155–64. Epub 2014/04/05. 10.1038/leu.2014.119 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0222228.ref044] 44.Kalin JH, Wu M, Gomez AV, Song Y, Das J, Hayward D, et al. Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nat Commun. 2018;9(1):53 Epub 2018/01/06. 10.1038/s41467-017-02242-4 [DOI] [PMC free article] [PubMed] [Google Scholar]

PERMALINK

Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines

Darcy Welch

Elliot Kahen

Brooke Fridley

Andrew S Brohl

Christopher L Cubitt

Damon R Reed

Roles

Abstract

Introduction

Materials and methods

Investigational agents

Table 1. Summary of agents tested, mechanism of action, selected pharmacokinetic data, and experimental values—top concentrations and AUC at top concentrations for each drug in each cell line.

Cell culture

Table 2. Summary of Ewing cell lines.

Cell viability assays

Single-agent screening

Two-drug combination screening

Order of addition assays

Statistical methods

Results

NuRD complex directed therapeutics demonstrate considerable in vitro activity at clinically achievable levels

Fig 1. Single agent dose response plots for 7 tested agents against 4 ES cell lines demonstrate efficacy at clinically achievable concentrations.

The LSD1 inhibitor SP2509 and the HDAC inhibitor romidepsin are synergistic with conventional chemotherapeutic agents in vitro

Fig 2. Overview of combination efficacy for SP2509 and romidepsin combinations.

SP2509 enhances efficacy of VIT (vincristine, irinotecan, and temozolomide)

Fig 3. Vincristine, irinotecan, temozolomide, and SP2509 order of addition.

Table 3. Single agent dose response IC50s at 24-hours and 96-hours after treatment, ± standard error of the mean.

Discussion

Fig 4. Correlation analysis of FA for all combinations tested.

Fig 5. Clinical schedules and corresponding PK predicted activities for combinations of interest.

Supporting information

Acknowledgments

Abbreviations

Data Availability

Funding Statement

References

Decision Letter 0

Arun Rishi

Roles

Author response to Decision Letter 0

Decision Letter 1

Arun Rishi

Roles

Acceptance letter

Arun Rishi

Roles

Associated Data

Supplementary Materials

Data Availability Statement

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases

Table 3. Single agent dose response IC₅₀s at 24-hours and 96-hours after treatment, ± standard error of the mean.